EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CAPOX vs. FOLFOX for Colorectal Cancer—Real World Outcomes in Ontario, Canada

Deepro Chowdhury, Gregory R Pond iD, John R Goffin

Current Oncology · 31.07.2025 · 32 (8) · 435

DOI: 10.3390/curroncol32080435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 31.07.2025. Verfasst von Deepro Chowdhury und 2 weiteren Autor:innen. Beteiligte Einrichtung: Windsor Regional Hospital, Windsor, ON N8W 2X3, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAPOX and FOLFOX are widely used chemotherapy regimens for colorectal cancer (CRC). The superiority of one regimen over the other in a real-world setting (RWE) could have significant clinical implications given their common use, but such RWE is limited. This study analyzed provincial database records of 13,461 Canadian patients treated from 2005 to 2017. The primary outcomes were rates of Emergency Department visits and/or hospitalizations (ED/H) and overall survival (OS). CAPOX was used less frequently (8.4%) than FOLFOX (91.6%), often in older patients (p < 0.003 for Stage I–III; p < 0.001 for Stage IV). CAPOX recipients had shorter treatment durations (median 15 vs. 20 weeks, p = 0.002) and higher unadjusted ED/H rates (60.8% vs. 50.9%, p < 0.001), though this difference was nonsignificant on multivariate analysis (MVA) (HR 1.05 (0.92, 1.20), p = 0.466). Patients receiving CAPOX had worse OS than those on FOLFOX, (5-year OS 70.1% vs. 77.2% (p < 0.001) non-metastatic; 16.6% vs. 33.2% (p < 0.001) metastatic). MVA confirmed inferior OS with CAPOX (HR 1.42, p < 0.001). Other predictors of shorter OS included older age, male sex, comorbidities, rural residence, and lower income. This administrative data is at risk of bias but highlights the need for careful patient selection and informed treatment decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedLeucovorinOrganoplatinum CompoundsAgedOntarioFluorouracilOxaliplatinCapecitabineAdultTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

CAPOX vs. FOLFOXchemotherapy regimenscolorectal canceroverall survivalreal-world outcomes

Substanzen

LeucovorinOrganoplatinum CompoundsFluorouracilOxaliplatinCapecitabine

Autor:innen und Institutionen

  • Windsor Regional Hospital, Windsor, ON N8W 2X3, Canada.
  • Escarpment Cancer Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada.
  • Department of Oncology, McMaster University, Juravinski Cancer Centre, 699 Concession St., Hamilton, ON L8V 5C2, Canada.

ORCID-Profile: Gregory R Pond

Zitieren

APA

Chowdhury, D., Pond, G. R., & Goffin, J. R. (2025). CAPOX vs. FOLFOX for Colorectal Cancer—Real World Outcomes in Ontario, Canada. Current Oncology, 32(8), 435. https://doi.org/10.3390/curroncol32080435

Vancouver

Chowdhury D, Pond GR, Goffin JR. CAPOX vs. FOLFOX for Colorectal Cancer—Real World Outcomes in Ontario, Canada. Current Oncology. 2025;32(8):435. doi:10.3390/curroncol32080435

BibTeX
@article{Chowdhury2025,
  author = {Chowdhury, Deepro and Pond, Gregory R and Goffin, John R},
  title = {CAPOX vs. FOLFOX for Colorectal Cancer—Real World Outcomes in Ontario, Canada},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {8},
  pages = {435},
  doi = {10.3390/curroncol32080435}
}
Kostenlos starten →